Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEJ025B afatinib plus pemetrexed and carboplatin after first-line osimertinib failure in EGFR-mutated non-squamous NSCLC
jRCTs021200005Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib, pemetrexed and carboplatin in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Primary endpoint: Progression-free survival rate at 6 months. Started Jun 2020; status: completed.
02
Drugs
afatinibpemetrexedcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs021200005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021200005.